Subscription by and conditional allocation to primary insiders in Pryme N.V. in a private placement
Pryme N.V. (PRYME) · publisert 25. mars 2024 kl. 23:25 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Stichting Multistrat nærstående | – | subscription Emisjon/tegning | 1 056 078 | 0,9469 EUR | 25. mars 2024 | NL00150005Z1 | Outside a trading venue g) Additional Information Subject to EGM approval | rules |
| Circular Plastics Coöperatief U.A. nærstående | – | subscription Emisjon/tegning | 996 078 | 0,9469 EUR | 25. mars 2024 | NL00150005Z1 | Outside a trading venue g) Additional Information Subject to EGM approval | rules |
Vedlegg
- Notification of transactions by primary insiders and their close associates_Stichting Multistrat_Boudewijn van Vliet_25-MARCH-2024.pdf (tekst hentet ut)
- Notification of transactions by primary insiders and their close associates_Circular Plastics Cooperatief U.A._Jan Willem Muller_25-MARCH-2024.pdf (tekst hentet ut)
- Pryme N.V. - Subscription by and conditional allocation to primary insiders in Pryme N.V. in a private placement 25 March 2024.pdf (tekst hentet ut)
Meldingstekst
Subscription by and conditional allocation to primary insiders in Pryme N.V. in a private placement.
Rotterdam, 25 March 2024
Reference is made to the private placement announced on March 25th, 2024 subject to shareholder approval in an extraordinary general meeting to be held on April 9th, 2024 (the “Private Placement”).
Circular Plastics Coöperatief U.A., represented on the board of directors of Pryme N.V. ("Pryme") has on 25 March 2024 been allocated 996,078 Offer Shares corresponding to an investment of EUR € 0.9 million in the Private Placement subject to the approval by the Company’s shareholders.
Stichting Multistrat, represented on the board of directors of Pryme has on 25 March 2024 been allocated 1,056,078 Offer Shares corresponding to an investment of EUR € 1.0 million in the Private Placement subject to the approval by the Company’s shareholders.
For additional information, please see the attached forms.